0ae6d322-a938-4752-aac6-226e6687a297
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.400
- CHOLESTEROL_HOMEOSTASIS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- INFLAMMATORY_RESPONSE+0.270
- DNA_REPAIR+0.250
- HEME_METABOLISM+0.220
- IL2_STAT5_SIGNALING+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- UV_RESPONSE_DN-0.350
- MITOTIC_SPINDLE-0.340
- G2M_CHECKPOINT-0.300
- TGF_BETA_SIGNALING-0.250
- HEDGEHOG_SIGNALING-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.220
- ANGIOGENESIS-0.180
- E2F_TARGETS-0.160
- MYOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208892 | — | — | 0.801 |
| 2 | 526e2e75-cc0e-4c03-916c-908fbc271854 | — | — | 0.764 |
| 3 | DRR168511 | — | — | 0.761 |
| 4 | 6c0e101a-5eeb-46c7-9143-e78dc144d503 | — | — | 0.742 |
| 5 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.727 |
| 6 | fe1628d5-92d9-4e5c-a441-531b699014f1 | — | — | 0.720 |
| 7 | R49 | — | — | 0.718 |
| 8 | SRR5088844 | — | — | 0.716 |
| 9 | 6e0c14ea-3eb3-424a-bc12-fb127ac1a777 | — | — | 0.713 |
| 10 | TCGA-CV-6955-01A-11R-2016-07 | — | — | 0.711 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |